The company’s consolidated profit excluding minority interest dropped to EGP 105.826 million in January-September from EGP 46.728 million a year earlier ...
GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...
GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market ... of access in Egypt earlier than other companies. By buying two successful local ...
Andrew Witty became CEO of UnitedHealth Group in 2021, but this isn’t his first medical executive gig—he also served as CEO ...
Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company ...
DPA International on MSN14d
British pharmaceutical company GSK reports drop in Q3 pre-tax profitBritish pharmaceutical company GSK reported on Wednesday that its third-quarter profit before tax dropped to £64 million ($83 ...
No Data For Bulk Deal. *Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline ...
GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs 252 crore in the September quarter, aided by robust sales across segments.
Meanwhile, the value of five pharmaceutical companies fell in 2017 as Merck & Co, Celgene, GlaxoSmithKline (GSK), Allergan and Shire all saw their market capitalisation decline. But there was ...
GlaxoSmithKline Pharmaceuticals reports a 16% jump in Q2 net profit to Rs 252 crore, driven by strong sales across segments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback